These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 18299305)

  • 1. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
    Bergen R; Black S; Shinefield H; Lewis E; Ray P; Hansen J; Walker R; Hessel C; Cordova J; Mendelman PM
    Pediatr Infect Dis J; 2004 Feb; 23(2):138-44. PubMed ID: 14872180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.
    Vesikari T; Fleming DM; Aristegui JF; Vertruyen A; Ashkenazi S; Rappaport R; Skinner J; Saville MK; Gruber WC; Forrest BD;
    Pediatrics; 2006 Dec; 118(6):2298-312. PubMed ID: 17142512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live attenuated versus inactivated influenza vaccine in infants and young children.
    Belshe RB; Edwards KM; Vesikari T; Black SV; Walker RE; Hultquist M; Kemble G; Connor EM;
    N Engl J Med; 2007 Feb; 356(7):685-96. PubMed ID: 17301299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
    Tam JS; Capeding MR; Lum LC; Chotpitayasunondh T; Jiang Z; Huang LM; Lee BW; Qian Y; Samakoses R; Lolekha S; Rajamohanan KP; Narayanan SN; Kirubakaran C; Rappaport R; Razmpour A; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2007 Jul; 26(7):619-28. PubMed ID: 17596805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
    King JC; Treanor J; Fast PE; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith WE; Lambert JS; Belshe RB
    J Infect Dis; 2000 Feb; 181(2):725-8. PubMed ID: 10669363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
    Block SL; Toback SL; Yi T; Ambrose CS
    Clin Ther; 2009 Oct; 31(10):2140-7. PubMed ID: 19922885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of inactivated trivalent influenza vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Shah SI; Caprio M; Hendricks-Munoz K
    Pediatrics; 2007 Sep; 120(3):e617-21. PubMed ID: 17766502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
    Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
    Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
    Belshe RB; Gruber WC
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1947-51. PubMed ID: 11779396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.